



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



⑪ Publication number: **0 246 864 B1**

⑫ **EUROPEAN PATENT SPECIFICATION**

④③ Date of publication of patent specification: 13.07.94 ⑤① Int. Cl.<sup>5</sup>: **C12Q 1/68**

②① Application number: **87304433.3**

②② Date of filing: **19.05.87**

⑤④ **Hybridisation probes.**

③① Priority: **19.05.86 GB 8612087**

④③ Date of publication of application:  
**25.11.87 Bulletin 87/48**

④⑤ Publication of the grant of the patent:  
**13.07.94 Bulletin 94/28**

⑥④ Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**

⑤⑥ References cited:  
**EP-A- 0 070 685**  
**EP-A- 0 130 515**  
**EP-A- 0 185 494**  
**EP-A- 0 224 126**  
**WO-A-87/06956**

**NUCLEIC ACIDS RESEARCH, vol. 14, no. 22,**  
**1986, Oxford (GB); P.K. ROGAN, p.**  
**9219&NUM;**

⑦③ Proprietor: **BIO-RAD LABORATORIES, INC.**  
**1000 Alfred Nobel Drive**  
**Hercules California 94547(US)**

⑦② Inventor: **Carr, Francis Joseph**  
**16 Snabwood Close**  
**Little Neston South Wirral L64 0UP(GB)**

⑦④ Representative: **Thomson, Paul Anthony et al**  
**Potts, Kerr & Co.**  
**15, Hamilton Square**  
**Birkenhead Merseyside L41 6BR (GB)**

**EP 0 246 864 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

## Description

The present invention relates to a method for the use of hybridisation probes, hybridisation probes therefor and kits for use in such a method. The present invention is particularly concerned with discriminating a specific base sequence from a variant base sequence and relates in particular to the advantages which may be obtained by subjecting adjacent segments of a target base sequence to hybridisation with a detectable first nucleotide probe and a second nucleotide probe.

The present invention thus relates *inter alia* to discriminating specific base sequences whilst ameliorating the problem of background non-specific hybridisation commonly encountered with hybridisation of short oligonucleotide probes to complex genomes.

Nucleic acid hybridisation analysis is a technique of wide applicability in the fields of biomedical research and recombinant DNA technology. Thus for example hybridisation probes are useful for detecting, monitoring, locating and isolating nucleic acids and other molecules of scientific or clinical interest. Particularly useful are small oligonucleotide hybridisation probes which may for example be used to detect changes in DNA base sequences in relation to certain disease states such as phenylketonuria, alpha-antitrypsin deficiency, alpha- and beta-thalassaemia and sickle cell anaemia. These disease states are often associated with known single point mutations in genes.

Whilst short oligonucleotide hybridisation probes are of considerable utility, they are usually associated with a high background of non specific hybridisation particularly when used for analysis of the genomes of higher organisms. This problem arises from the greater complexity of the genome. Thus for example mammals may contain of the order of a thousand-fold more DNA per cell than bacteria, and many of the nucleotide sequences may be repeated. For any given nucleotide probe therefore stable duplexes (hereinafter also referred to as hybrids) other than the desired duplex will usually be formed. This problem is particularly exacerbated by using very high oligonucleotide concentrations in order to accelerate the hybridisation process. This problem can be circumvented by using gel electrophoresis to resolve different DNA (or RNA) fragments before oligonucleotide hybridisation to ensure that a specifically hybridising fragment is resolved from non-specifically hybridising fragments. For example, Woo *et al* (Banbury Report, Recombinant DNA Applications to Human Disease, Cold Spring Harbor Laboratory (1983) p105-110) employ the Southern transfer technique to resolve small restriction fragments hybridising to an alpha<sub>1</sub>-antitrypsin oligonucleotide probe from higher molecular weight species of DNA which also hybridise to this probe.

Oligonucleotide hybridisation analysis of complex genomes using gel electrophoresis requires the preparation of pure DNA (or RNA) molecules from the organisms, fragmentation of DNA molecules by treatment with restriction endonucleases and, in most cases, transfer of resolved DNA (or RNA) molecules from the gel to a solid support for hybridisation. The complexity of this procedure makes it unsuitable for routine diagnostic use and difficult to automate.

Simpler methods for hybridisation analysis with specifically hybridising long polynucleotide probes are exemplified by J Brandsma and G Miller, Proc. Nat. Acad. Sci.(USA) Vol 77 (1980) p6851-6855 for DNA and by T. Manser and M L Gefter Proc.Natl. Acad.Sci USA Vol 81 (1984) p2470-2474 for RNA and involve directly immobilising DNA or RNA from crude cellular lysates onto solid supports. Because of non-specific hybridisation, such direct immobilisation methods are not usually compatible with the use of oligonucleotide probes.

EP-A-0 185 494 which belongs to the state of the art in the sense of Article 54(3) EPC relates to a method of testing for the presence or absence of a target nucleotide sequence in a sample containing denatured nucleic acid. The said method specifically requires hybridization conditions in which a first probe (the diagnostic probe) only binds to the target nucleic acid if it is complementary to the diagnostic portion of the target sequence. A second probe (the contiguous probe) is complementary to a nucleotide sequence contiguous with the diagnostic portion. If the diagnostic probe is bound it will then be ligated to the contiguous probe and detected. Accordingly, if the target sequence is not identical to the diagnostic probe no binding will occur.

In addition to the above problem of background non-specific hybridisation the present invention also relates *inter alia* to simplifying the detection of translocations which hitherto have only been detectable by gel methods.

The present invention is thus based, at least in part, on the discovery of a method for discriminating between alternative nucleotide sequences whilst ameliorating the above-mentioned problems. The method of the present invention is thus of *inter alia* simplifying the detection of translocations and enabling a mutation in a given base sequence to be readily detected by for example allowing meaningful analysis of directly immobilised DNA or RNA samples or alternatively DNA or RNA samples in solution. In

this connection it is known that the shorter the nucleotide probe the poorer is the selectivity of hybridisation and thus correspondingly the greater is the background. Moreover the shorter the nucleotide probe the weaker is the stability of the duplex formed as measured by its melting temperature ( $T_m$ ) which is the temperature of the midpoint of thermal transition. The present invention is based at least in part, on the discovery that the different hybridisation properties of a short nucleotide probe relative to a comparatively longer nucleotide probe may be exploited to advantage in discriminating between alternative nucleotide sequences, whilst ameliorating the above-mentioned problems.

The present invention is further based on the discovery of a method which substantially simplifies the hybridisation analysis thus providing a robust technique for discriminating between alternative nucleotide sequences.

Thus according to one feature of the present invention there is provided a method for discriminating between alternative nucleotide sequences, which method comprises subjecting adjacent segments of a target base sequence to hybridisation with a detectable first nucleotide probe and with a second nucleotide probe, to form a hybrid, the nucleotide sequence of the first and second probe being such that where they form a split probe hybrid with a complementary target sequence they may subsequently be linked subjecting any hybrid obtained to linkage, followed by detection of any hybrid obtained;

the DNA sequence of the detectable first nucleotide probe and of the second nucleotide probe being such that a potential mismatch in the target sequence lies either between the said probes or at the terminal end of one of said probes, which terminal end is contiguous with the other of the said probes;

the method being effected such that a complementary target sequence is discriminated from a target sequence with one or more non-complementary nucleotides.

Where necessary any hybrid obtained following linkage may be subjected to selective denaturing.

The presence of a linked probe may be detected by any convenient means for example selective denaturing or where one of the probes carries one member of a binding pair then by use of the other member of the binding pair. Appropriate examples of binding pairs are discussed hereinafter. It will be appreciated that one might identify either a complementary or a non-complementary target sequence by the absence of a detectable hybrid and this is included within the scope of the present invention.

It will be appreciated that hitherto discriminatory specificity has been achieved by careful manipulation of the temperature of hybridisation and washing of bound discriminatory probes. In the present invention the probes are designed to hybridise to the target sequence on either side of a potential mismatch, there being a gap, preferably a single nucleotide gap, between the probes or the probes may be designed to hybridise to contiguous sequences in the target sequence any potential mismatch being present at the terminal end of one of the probes which terminal end is contiguous with the other probe. The effect of the present invention is that specificity is mainly the result of the interaction between two independently interacting probes and the means of linking the aforesaid probes, for example T4 DNA ligase. Thus the present invention enables a method of discrimination to be effected in which linkage e.g. ligation by for example T4 DNA ligase is expected to be less efficient where the residue(s) at either the 3' or the 5' site of the contiguous probes to be joined are not complementary to the sequence to which they are hybridised. Similarly where a gap, preferably a single nucleotide gap, is present between the two probes the present invention enables a method of discrimination to be effected in which incorporation of nucleotides with for example the Klenow fragment of DNA polymerase I or calf thymus DNA polymerase alpha to fill in the gap and allow linkage, with for example DNA ligase, will be significantly less efficient where the deoxy nucleotide triphosphate added, to for example the DNA polymerase reaction mixture is not complementary to the base residue under examination.

The present invention thus enables the hybridisation analysis to be substantially simplified and allows the production of a robust technique for discriminating between alternative nucleotide sequences. Thus for example the need to rely on the use of a hybridisation or wash within a narrow temperature range and for a specific time may be obviated thus overcoming the difficulties inherent in any technique which relies on narrow margins of error. The present invention even renders it possible in at least certain embodiments to effect the hybridisation analysis at room temperature.

The method of the present invention may for example be effected either by detection of a detectable signal, resulting from complementary hybrid formation where a complementary target sequence is present, the hybrid, if necessary, being denatured prior to detection; or by failure to detect a detectable signal, resulting from the absence of hybrid formation across a mismatch or from selective denaturation of any hybrid formed, where a target sequence with one or more non-complementary nucleotides is present.

Thus whilst the first nucleotide probe must be detectable the second nucleotide may or may not be detectable depending on the embodiment of the method to be employed.

The term detectable is used herein to mean capable of detection. Thus the first nucleotide probe need not carry a signalling means such as a radioactive label or a non-radioactive signalling complex, although such may be present, provided that the probe may subsequently be treated to render it capable of signalling. It is thus possible to discriminate between sequences in a complex genome differing by as little as one base pair.

Where a split probe hybrid would be formed following hybridisation, with a complementary target base sequence, any hybrid obtained is subjected to a linking reaction for linking the detectable first nucleotide probe to the second nucleotide probe, any hybrid obtained being subjected to appropriate treatment whereby any hybrid present, in which linkage of the detectable first nucleotide probe to second nucleotide probe has not been effected, is denatured whereas no denaturation is effected for a perfectly complementary detectable linked oligonucleotide-target sequence hybrid. Where a probe is designed to hybridise to a portion of the target sequence which contains a suspected mismatch, the probe will generally be an oligonucleotide (as hereinafter defined). Appropriate treatment may for example include selective denaturation or one of the probes may comprise one member of a binding pair. Linkage of adjacent stable hybrids of first and second nucleotide probes results in greater hybrid thermal stability for the detectable oligonucleotide hybridised to a specific target sequence as opposed to detectable oligonucleotides hybridised to non specific target sequences with no adjacent oligonucleotide probe present.

The expression "oligonucleotide" as used herein means a nucleotide sequence which is either incapable of forming a hybrid with a target sequence containing as little as a single base pair mismatch or is capable of forming such a hybrid, such a hybrid however being destabilised by the presence of as little as a single base pair mismatch such that it may be selectively denatured under conditions which would not denature a corresponding perfectly complementary hybrid.

It will be appreciated that the potential variant sequence may be present in the segment of the target sequence to which the detectable first nucleotide probe hybridises, it may be present in the segment of the target sequence to which the second nucleotide probe hybridises or it may be present between the said segments. The probes will be designed such that where the potential variant sequence is present in the segment of the target sequence to which either the detectable first nucleotide probe or the second nucleotide probe hybridises, then the potential variant sequence will be at the terminal end of one of said probes, which terminal end is contiguous with the other of the said probes.

Thus for example where the potential variant sequence is present in the segment of the target sequence to which the second nucleotide probe hybridises, formation of a split probe hybrid, will result either in formation of a weak hybrid of the second probe across the mismatch or if the second probe is very short no hybridisation at all. Where a weak hybrid is formed selective denaturing will result in denaturing of the second probe hybrid. If the hybrid obtained is then subjected to linking, linkage can only take place where the second probe is hybridised to the target sequence and thus where no mismatch exists in the second probe: target sequence hybrid. If the hybrid obtained after linking is subjected to selective denaturing any hybrid present in which the first probe alone is hybridised to the target sequence without linkage to the second probe will denature thus leaving detectable probe hybridised only to the target sequence which does not contain a mismatch with the complementary sequence of the second probe.

The first or second nucleotide probe may if desired have one member of a binding pair. Generally the one member of a binding pair will be carried by, or be part of, the second nucleotide probe. The other member of the binding pair may be in solution or on a support. Thus where appropriate, the second nucleotide probe linked to the detectable first nucleotide probe may be isolated on a support carrying the other member of the binding pair. Such a binding pair may for example be a protein-ligand or antigen-antibody interaction such as an avidin-biotin or dinitrophenyl-antidinitrophenyl antibody interaction.

Indeed one member of the binding pair may be a nucleotide sequence, which sequence may be a portion of the probe sequence or may be a nucleotide sequence branch on the probe. The other member of the binding pair may for example be a protein which binds to the nucleotide sequence or another nucleotide sequence to which it hybridises.

The hybridisation and/or selective denaturation is preferably effected at a temperature selected to give effective hybridisation selectivity, preferably maximum hybridisation selectivity for the specific length of the linked probe. Advantageously the hybridisation and/or selective denaturation is effected in aqueous solution at an elevated temperature suitable for selective hybridisation to a mammalian genome which for a split probe when linked is preferably above 60°C generally about 68°C. Alternatively hybridisation and/or selective denaturation of such a split probe when linked may be effected at a lower temperature in the presence of an organic solvent which is effective to destabilize the hybrid, such as a solvent containing formamide. For example where about 50% formamide is used the hybridisation and/or selective denaturation is effected at about 42°C.

In a further embodiment of the present invention there is provided a method of hybridisation probing which comprises subjecting adjacent segments of the target base sequence to hybridisation with a detectable first nucleotide probe and with a second nucleotide probe such that a split probe hybrid would be formed with a complementary target sequence, where necessary subjecting the hybrid obtained to selective denaturing whereby to denature whichever of the first and second nucleotide probes is hybridised to a portion of the target base sequence with one or more non-complementary nucleotides and subsequently subjecting the hybrid obtained to a linking reaction whereby to link together the detectable first nucleotide probe to the second nucleotide probe and where necessary subjecting the hybrid obtained to selective denaturation whereby to discriminate between a target sequence complementary to the first and second nucleotide probes and a target sequence with one or more nucleotides non-complementary to one of the first and second nucleotide probes.

The hybridisation or selective denaturation may be effected for example at a temperature above the melting temperature of the split or single nucleotide probe hybrid but below the melting temperature of the linked probe hybrid or in the presence of an organic solvent effective to destabilise the hybrid as discussed above. Where hybridisation is effected under selective denaturing conditions a further selective denaturing step after the hybridisation but before linking may be avoided.

The first and second nucleotide probes may be linked by any convenient means known per se such as for example by enzymatic ligation using, for example, a DNA ligase or by covalent/non-covalent linking using for example a biotin-avidin cross-link.

The detectable first nucleotide probe and/or the second nucleotide probe may initially not be capable of being linked, e.g. ligated, together until the gap(s) between them is (are) filled with DNA polymerase in the presence of the target sequence of interest.

The effect of linking the detectable first nucleotide probe and second nucleotide probe is to increase the thermal stability of the cross-linked probe hybrid obtained over the corresponding detectable probe hybrid alone. Thus for example the temperature of the linked probe hybrid may be increased to a temperature which denatures the corresponding split probe hybrids or a corresponding hybrid in which only one of the detectable first nucleotide probe and second nucleotide probes is hybridised to the target base sequence. The linked probe hybrid which includes the complementary target base sequence is thus left intact. The method of the present invention thus enables one to discriminate a base sequence which is perfectly complementary to the detectable probe sequence from alternative sequences.

It will be appreciated that while the above embodiment of the invention is most useful for directing oligonucleotides to specific hybridisation sites in complex genomes in order for example, to analyse for the presence of point mutations it is also of use for analysis of other variations in complex genomes such as translocations. For analysis of translocations, it is preferred that the non-detectable second polynucleotide of a split probe will have one member of a binding pair associated therewith and will hybridise to genomic sequences adjacent to potential translocation breakpoints. The detectable probe will preferably be several kilobases long and span a region of potential translocation breakpoints. Quantitative linkage of polynucleotides comprising the split probe following hybridisation will only occur where the genomic region is contiguous and uninterrupted by translocations. The occurrence of a translocation will preclude a proportion of the detectable probe from linking to the non-detectable polynucleotide. On subsequent denaturation of hybridised polynucleotide and application of the other member of the binding pair, a proportion of the detectable polynucleotide will not then be found to be associated with the polynucleotide complexed with the other member of the binding pair. The binding pair will preferably comprise an antigen-antibody or a biotin-avidin interaction whereby, for example, denatured hybrids are passed through a solid phase complexed with one member of the binding pair and the eluate analysed for the presence of the detectable probe.

Thus in a further embodiment of the invention we provide a method for the analysis of translocations in a target base sequence e.g. a complex genome in which the detectable first nucleotide probe is adapted to hybridise across a region of potential translocation(s) and the non-detectable second nucleotide probe is adapted to hybridise to sequences adjacent to said potential translocation(s), the non-detectable second nucleotide probe carrying one member of a binding pair, the method comprising formation of a split probe hybrid which is subjected to linking to form a linked probe hybrid which hybrid is then denatured.

In another embodiment of the present invention, there is provided a method as hereinbefore defined wherein each of the detectable first nucleotide probe and second nucleotide probe carry a moiety such that after hybrid formation, and denaturation where appropriate, a signal is only detectable if a nucleotide sequence is obtained which carries both the moiety attached to the detectable first nucleotide probe and the moiety attached to the second nucleotide probe.

The nucleotide probes may for example be oligonucleotide probes.

The method of this embodiment might for example be effected using non-radioactive energy transfer procedures (see for example European Patent Publication No. 70685 of Standard Oil Co.) or enzyme channelling techniques (see for example European Patent Publication No. 95087 of Syva Co.). Thus this embodiment may provide a homogenous assay for a specific target nucleotide sequence.

5 In another embodiment of the invention there is provided a method for discriminating between alternative nucleotide sequences in which a target sequence is subjected to hybridisation with more than two oligonucleotide probes such that where a complementary target sequence is present a split probe hybrid is obtained, the detectable first nucleotide probe being a terminal oligonucleotide probe which is detectable and the second nucleotide probe being the other terminal oligonucleotide probe which has  
10 attached thereto one member of a binding pair, individual other oligonucleotide probe(s) being hybridised separately but adjacently to a contiguous target sequence between the said terminal oligonucleotide probes, the hybrid obtained is then subjected to selective denaturation whereby to denature any oligonucleotide probe hybridised to the target sequence across a base pair mismatch, and the individual oligonucleotide probes linked to join the detectable oligonucleotide probe to the oligonucleotide probe having one member  
15 of a binding pair attached thereto to form a linked probe hybrid which is then denatured and contacted with the other member of the binding pair whereby the detectable linked probe nucleotide sequence including the said binding pair may be separated from other nucleotide sequences. Thus one terminal oligonucleotide (hybridising adjacent to a series of other oligonucleotides) for example has attached thereto a detectable signalling moiety while the other terminal oligonucleotide has attached a moiety forming part of a binding  
20 pair the moiety being effective to enable the oligonucleotide to be recovered in solution from a mixture containing other nucleotide sequences. Adjacently hybridised oligonucleotides are linked together by appropriate treatment in order to effectively join the signalling and binding moieties via a linked probe where no oligonucleotide hybrid is denatured prior to linkage. Loss of any individual oligonucleotide hybrid results in subsequent failure to join the signalling and binding moieties. The linked probe hybrid is  
25 denatured and contacted with the other member of the binding pair which recognises one terminal oligonucleotide in the linked probe. The linked probe may thus if desired be separated from other oligonucleotides in the mixture and then analysed for the presence of the detectable moiety

Thus the association of the binding oligonucleotide with the signalling oligonucleotide is dependent on the presence, upon linking of adjacently hybridised oligonucleotides, of all adjacent oligonucleotides  
30 between the hybridised signalling oligonucleotide and the binding oligonucleotide. The binding pair effecting separation of the linked probe with an associated binding moiety may be avidin and biotin or an antigen and associated specific antibody. This embodiment provides for analysis of longer stretches of target nucleotide sequence than with just two adjacent hybridising linked or split probes as in other embodiments.

A further embodiment of the present invention comprises hybridising the detectable first nucleotide  
35 probe and second nucleotide probe to each side of a potential variant sequence in a target sequence and subsequently attempting to link the said probes, preferably by the use of DNA polymerase introducing a nucleotide(s) complementary to either the normal or the suspected variant sequence and ligation, followed by detection of any hybrid obtained. Such detection may for example be effected by subjecting any hybrid obtained to selective denaturing whereby any hybrid present, in which linkage of the detectable first  
40 nucleotide probe to the second nucleotide probe has not been effected, is denatured.

The DNA polymerase used may for example be the Klenow fragment of DNA polymerase I or calf thymus DNA polymerase alpha. Ligation is preferably effected with DNA ligase. The detectable first nucleotide probe and second nucleotide probe are preferably such that they hybridise to the target sequence whereby to leave a gap of a single nucleotide between the said probes.

45 Where it is desired that the nucleotide probe should carry a signal or a residue capable of producing a signal, such signals or residues may be known per se e.g. a radioactive label.

The residue which is capable of producing a non-radioisotopic signal may alternatively comprise a signalling part normally separated from the oligonucleotide by a spacer group. This spacer group may if desired be linked to the signalling part of the complex by a direct covalent link or by a protein-ligand or  
50 antigen-antibody interaction, for example, an avidin-biotin or dinitrophenyl-antidinitrophenyl antibody interaction. It will be understood that the signalling part of the residue may itself be capable of signalling or may be capable of producing a signal by interaction with an appropriate agent according to methods known per se. Thus, for example a preferred signalling part of the covalently attached residue incorporates a system for producing an enzymatically-activated production of colour change. Preferred enzyme systems involve  
55 alkaline phosphatase, acid phosphatase, beta galactosidase, luciferase, or horseradish peroxidase. Such enzyme systems are not themselves capable of signalling, but are capable of producing a signal in the presence of an appropriate substrate according to methods known per se. The signalling part of the covalently-attached residue may operate according to any conventional technique such as for example by

luminescence, fluorescence or by means of colour.

In use it will generally be necessary for the nucleic acid probe to detect minute amounts of the fully complementary oligonucleotide sequence. In such circumstances it will be advantageous to incorporate within the probe a means of amplifying the signal. The amplification can be carried out by known techniques, for example using one or more of the systems described in European Patent Publications 27036 (Self), 49606 (Self), 58539 (Self) and 60123 (Self).

According to a further feature of the present invention there are provided split probe hybrids which comprise a detectable first nucleotide probe and a second nucleotide probe hybridised to adjacent segments of a target base sequence, the detectable first nucleotide probe being capable of linkage to the second nucleotide probe, characterised in that the detectable first nucleotide probe and/or the second nucleotide probe are hybridized to either side of a variant sequence associated with a disease state or to the corresponding normal sequence; or are hybridised to the target base sequence such that a variant base sequence associated with a disease state therein is at the terminal end of one of said probes, which terminal end is contiguous with the other of said probes or are hybridised to the corresponding normal sequence.

The non-nucleotidyl cross-link may for example be a disulphide link or a biotin-avidin link.

At least the first nucleotide probe is detectable and thus preferably carries a signal or a residue capable of producing a signal as described above.

In order to enable the method of the present invention to be effected conveniently it will generally be advantageous to incorporate the nucleotide probes in a kit and this kit is therefore regarded as a further feature of the invention.

Thus according to a further feature of the present invention there is provided a kit for discriminating between alternative nucleotide sequences which comprises a detectable first nucleotide probe and a second nucleotide probe, each probe having a nucleotide sequence homologous to adjacent segments of a target sequence, a potential variant sequence being present in one of said segments or therebetween; the detectable first nucleotide probe and/or the second nucleotide probe being such that a potential variant sequence is at the terminal end of one of said probes, which terminal end is contiguous with the other of said probes or the potential variant sequence is present between said probes, the kit additionally containing a reagent(s) for linking said probes where the probes are not so linked.

The potential variant sequence will commonly be a point mutation associated with a disease state. In such a case the kit will preferably contain a detectable first nucleotide probe and second nucleotide probe for detecting a point mutation associated with a disease state as well as a detectable first nucleotide probe and a second nucleotide probe for detecting the corresponding normal sequence in which the point mutation was absent.

It will be appreciated in this regard that certain disease states are characterised by point mutations which appear in different regions of the human DNA genome. In such a case it would be important to determine that each relevant point mutation was present or absent and thus more than one set of probes (detectable first nucleotide probe and second nucleotide probe at least) would be employed, one set of probes to detect the presence or absence of each point mutation. It would also be advantageous to include in the kit set(s) of probes for the corresponding normal or variant sequence.

The kit will also advantageously contain means for extracting DNA and/or means for immobilising DNA on a solid support.

If desired at least one of the detectable first nucleotide probe and second nucleotide probe may carry one member of a binding pair, the other member of the binding pair being present for example on a solid support provided with the kit.

The kit will also comprise appropriate buffer solutions and/or washing solutions and will contain written or printed instructions for use of the kit according to the method of the present invention.

With reference to the drawings:-

Figures 1, 2 and 3 are autoradiographs in which I represents the DNA sequence of human interferon alpha<sub>2</sub> in the plasmid pIFS1101 as set out in Edge *et al*, Nucleic Acids Research Vol 11, (1983) p6419 to p6435 and K represents the DNA sequence which codes for the interferon alpha<sub>2</sub> analogue [Ala<sup>28</sup>]IFN-alpha<sub>2</sub> in which the codon TCC is replaced by GCT. This analogue base sequence is herein designated as pKQ.

Figure 4 is an autoradiograph in which lane M shows a signal corresponding to a 32 base long oligonucleotide marker band, lane 1 shows a signal corresponding to a 32 base long ligation product derived from oligonucleotides 11(-1) and 13 (see hereinafter) each with a single dCTP residue incorporated at its 3' end. Lanes 2 to 5 fail to show any signal corresponding to a 32 base long oligonucleotide.

Figure 5 shows an autoradiograph of aliquots of ligase reaction mixtures containing 5' OH trp 3, 5' OH trp 4, 5' <sup>32</sup>P CRN1 and 5' <sup>32</sup>P CRN2 carried out between 0 and 40 °C, these temperatures of incubation appearing at the top of the autoradiograph. O- is a no enzyme control. BPB indicates the position of the bromophenol blue marker dye.

5 Figure 6 shows an autoradiograph of aliquots of ligase reaction mixtures containing 5' OH trp 3, 5' OH trp 4, 5' <sup>32</sup>P CRN1 and 5' <sup>32</sup>P CRN4C carried out between 0 and 40 °C, these temperatures of incubation appearing at the top of the autoradiograph. O- is a no enzyme control. BPB indicates the position of the bromophenol blue marker dye.

10 Figure 7 shows an autoradiograph of aliquots of ligase reaction mixtures containing 5' OH trp 3, 5' OH trp 4, 5' <sup>32</sup>P CRN1 and 5' <sup>32</sup>P CRN6C carried out between 0 and 40 °C, these temperatures of incubation appearing at the top of the autoradiograph. O- is a no enzyme control. BPB indicates the position of the bromophenol blue marker dye.

The invention is illustrated, but not limited, by the following Examples. In the Examples, unless otherwise stated, the solutions are aqueous and the % values are w/v.

15 The constitution of various reagents is as follows:-

SSC is 0.15M NaCl + 0.015M sodium citrate;

Kinase buffer is 0.066M Tris.HCl pH 7.6, 1mM spermidine, 0.01M MgCl<sub>2</sub>, 15mM dithiothreitol and 0.2 mg/ml bovine serum albumin (BSA);

10 x CORE BUFFER is 500 mM Tris HCl pH8, 100 mM MgCl<sub>2</sub>, 500 mM NaCl;

20 10 x nick translation buffer is 0.5 M Tris.HCl (pH 7.2), 0.1 M MgSO<sub>4</sub>, 1mM dithiothreitol and 500 µg/ml BSA (Pentax, fraction V);

Triton®-X-100 is a polyoxyethylene ether surface active compound;

Ficoll is a non-ionic synthetic polymer of sucrose having a molecular weight of approximately 400,000 in dialysed and lyophilised form;

25 Nonidet P-40 is an octyl phenol ethylene oxide condensate containing an average of 9 moles ethylene oxide per molecule;

Denhardt's reagent is 0.2 g/l Ficoll 400,000, 0.2 g/l polyvinyl pyrrolidone (PVP) and 0.2 g/l bovine albumin (BA);

PBS - (phosphate buffered saline) is 0.01M sodium phosphate pH 7.4 and 0.13M NaCl;

30 SSPE is 10 mM sodium phosphate pH7, 0.18M NaCl and 1 mM EDTA;

The following contractions are used:-

DNA	deoxyribonucleic acid
tRNA	transfer ribonucleic acid
EDTA	ethylenediaminetetraacetic acid
35 PBS	phosphate buffered saline
SDS	sodium dodecyl sulphate
2 x SSC	double concentration SSC
6 x SSC	six times concentration of SSC
20 x SSC	twenty times concentration of SSC
40 BSA	bovine serum albumin
BA	bovine albumin
PVP	polyvinyl pyrrolidone
Tris	tris(hydroxymethyl)aminomethane
10 x Core	buffer ten times the concentration of CORE BUFFER
45 ATP	adenosine triphosphate
NP40	Nonidet P.40
10 x nick translation buffer	ten times the concentration of nick translation buffer

The following are trade marks

50 Minifold  
Triton-X-100  
CORE BUFFER  
Ficoll

#### EXAMPLE 1

55 Plasmids used for oligonucleotide hybridisation analysis were pIFS1101 (Edge et al., Nucleic Acids Research, Vol 11 (1983) p6419 to 6435) and a derivative thereof designated herein as pK9 in which the codon GCT coding for alanine is present at amino acid position 28 in place of the codon TCC which codes



for serine in HuIFN- $\alpha_2$ . Aliquots of 1  $\mu$ g, 100 ng and 10 ng were diluted to 153  $\mu$ l in water. To these were added 30  $\mu$ l 2MNaOH, 17  $\mu$ l 1M Tris.HCl pH7.4 and 100  $\mu$ l 20 x SSC (SSC is 0.15M NaCl, 0.015M sodium citrate). Samples were heated to 100 °C for 10 minutes, then placed on ice and 70  $\mu$ l 1M Tris.HCl pH7 was added. Dilutions of plasmid DNA were filtered onto BA 85 nitrocellulose filters (Schleicher and Schuell Keene, N.H., USA) using a Schleicher and Schuell Minifold II apparatus according to the manufacturer's instructions. The nitrocellulose paper was cut to fit the Minifold apparatus and wetted by floating on 2 x SSC before mounting in the apparatus. DNA samples were then applied to the wells and filtered at a rate of approximately 0.5 ml per minute. The nitrocellulose was then air dried for 10 minutes and baked at 80 °C for 2 hours *in vacuo*. The oligonucleotides 11 and 13 (Edge et al., see above) corresponding to the sequence of the synthetic interferon  $\alpha_2$  gene in pIFS1101 were used for hybridisation. Oligonucleotides 11 and 13 have the following DNA sequences:-

Oligonucleotide 11 5' CGTATCTCCCTGTTC 3'

Oligonucleotide 13 5' TCCTGTCTGAAAGAC 3'

Oligonucleotide 13 was labelled with  $^{32}$ P as follows: to 400 ng of oligonucleotide in 18.5  $\mu$ l H<sub>2</sub>O was added 20  $\mu$ l  $^{32}$ P gamma ATP (Adenosine 5'-[ $^{32}$ P]triphosphate, triethylammonium salt in aqueous solution, approx. 3000 Ci/nmol, 10  $\mu$ Ci/ $\mu$ l. Amersham International), 4.5  $\mu$ l 10 x kinase buffer (10 x buffer = 0.68M Tris. HCl pH7.6, 10mM spermidine, 0.1M MgCl<sub>2</sub>, 150mM dithiothreitol and 2 mg/ml bovine serum albumin (BSA, Nucleic Acid Enzyme Grade, Bethesda Research Laboratories)) and 2  $\mu$ l T4 polynucleotide kinase (5 units/ $\mu$ l, Boehringer Mannheim). After 1 hour at 37 °C, half of the sample was applied to a 4 ml column of Biogel P2 (Biorad; pre-equilibrated with 10mM Tris.HCl pH8, 1mMEDTA). The  $^{32}$ P labelled nucleotide was eluted in the void volume of the elution buffer comprising 10mM Tris.HCl pH8, 1mM EDTA. 100 ng of  $^{32}$ P labelled oligonucleotide probe was used for hybridisation together with 100 ng unlabelled oligonucleotide 11. Nitrocellulose filters onto which pIFS1101 or pK9 DNA had been immobilised were prehybridised for 2 hours at 68 °C in 5 x Denhardt's reagent (1 g/l Ficoll, 1 g/l polyvinylpyrrolidone, 1 g/l BA (bovine albumin, Fraction V, Miles Laboratories), 5 x SSC, 50mM sodium phosphate pH7, 1% glycine, 0.1% sodium dodecyl sulphate (SDS) and 100  $\mu$ g sonicated denatured herring sperm DNA (Sigma). Hybridisations were performed in 2 ml of 5 x SSC, 0.5% NP40 (BDH) and 250  $\mu$ g/ml tRNA (Sigma, type X-S) with 100 ng of either oligonucleotides 11 and 13 added together or, as a control, 100 ng of oligonucleotide 13 added alone. Hybridisations were performed overnight at room temperature. Filters were then washed in 6 x SSC, 0.06% sodium pyrophosphate and 20mM sodium phosphate buffer, pH7 for 5 minutes at room temperature and, after changing the wash buffer, for a further 3 minutes at room temperature. Filters were then treated with phosphate buffered saline (PBS; 0.01M sodium phosphate pH7.4, 0.13M NaCl) containing 2% BA and 0.1% Triton-X-100(BDH) for 30 minutes at 16 °C. Filters were then rinsed 5 times with PBS and 2% BA to remove the Triton-X-100. For cross-linking of hybridised probes, filters were treated with 66mM Tris.HCl pH7.6, 5mMMgCl<sub>2</sub>, 5mM dithiothreitol, 1mM ATP, 500  $\mu$ g/ml BSA and 0.3 U/ $\mu$ l T4 DNA ligase (Boehringer, 5U/ $\mu$ l). Incubation was for 80 minutes at 16 °C. Filters were then washed at 60 °C for 20 minutes in 6 x SSC, 0.06% sodium pyrophosphate and 20mM sodium phosphate pH7. The filters were then wrapped in Saran wrap and exposed to autoradiographic film for 2 days. Figure 1 shows that after the final wash at 60 °C, an appreciable autoradiographic signal was observed only for the plasmid pIFS1101 (I) where hybridised oligonucleotides 11 and 13 had been cross linked by ligation. A background signal corresponding to immobilised pK9 (K) was observed after hybridisation and cross linking of oligonucleotides 11 and 13. This background signal represented about 1% of the corresponding signal obtained for pIFS1101 and resulted from the minimal hybridisation of oligonucleotide 13 because of hybrid mismatches with the corresponding region of the plasmid pK9. Thus adjacent hybridised oligonucleotide probes were shown by this example to cross link efficiently by ligation on nitrocellulose filters. Moreover, with the experimental conditions described the ligation time could be reduced to 5 minutes without any loss of autoradiographic signal intensity.

## EXAMPLE 2

High molecular weight DNA was isolated from the lymphoblastoid line Daudi using the method of Blin and Stafford (Nucleic Acids Research, Vol.3 (1976) p2303). 200  $\mu$ g of Daudi DNA was diluted into 320  $\mu$ l H<sub>2</sub>O and to this was added 40  $\mu$ l of 10 x CORE BUFFER (Bethesda Research Laboratories) and 40  $\mu$ l EcoRI (50 units/ $\mu$ l Northumbria Biologicals, Cramlington, Northumberland, UK). Following an incubation at 37 °C for 3 hours, the solution was extracted with an equal volume of phenol/chloroform (1:1), then with 1 volume of chloroform and finally three times with 1 volume of H<sub>2</sub>O saturated ether. The DNA was adjusted to 0.3M sodium acetate and precipitated with 2 volumes of ice cold ethanol. The DNA pellet was washed in cold 70% ethanol and the pellet, dried and redissolved in 100  $\mu$ l H<sub>2</sub>O.

3 µg of the plasmids pIFS1101 and pK9 (see Example 1) were dissolved in 17 µl H<sub>2</sub>O and to this was added 2 µl 10 x CORE BUFFER and 1 µl EcoRI (see above). The mixture was incubated for 3 hours at 37°C and was followed by solvent extractions and EtOH precipitations as for the Daudi DNA above. The dried pellets were redissolved in 10 µl H<sub>2</sub>O.

5 10 µg of EcoRI digested Daudi DNA was mixed with 1 ng aliquots of either pIFS1101 or pK9 and subjected to gel electrophoresis on a 0.5% horizontal agarose gel as described in Maniatis et al (Molecular Cloning, A Laboratory Manual: Cold Spring Harbor Laboratory, 1982). Following electrophoresis, DNA was either transferred onto nitrocellulose filters by the Southern transfer procedure (Maniatis et al) for subsequent hybridisation or, alternatively, DNA was probed directly within dried agarose gels prepared as described by Studencki and Wallace (DNA, volume 3, p7 to 15 (1984)). For DNA transferred onto nitrocellulose filters hybridisation was as described in Example 1 except that the hybridisation temperature was 32°C using 100 ng oligonucleotide 11 and 100 ng <sup>32</sup>P labelled oligonucleotide 13 as probes. The filters were washed for 30 minutes at room temperature in 5 x SSC, 0.06% sodium pyrophosphate and 20mM sodium phosphate pH7 and then at 40°C for 15 minutes to remove most of the <sup>32</sup>P labelled oligonucleotide associated with the pK9 plasmid DNA. The filters were then exposed at -70°C to Kodak® X-Omat AR Film using intensifying screens. After this 40°C wash, a background signal derived from hybridisation to Daudi cell DNA was still evident as shown in Figure 2.

Dried agarose gels were hybridised directly with 100 ng of both oligonucleotides 11 and <sup>32</sup>P labelled 13 in 50 mM sodium phosphate pH7, 0.9 M NaCl, 5 mM EDTA, 0.3% SDS and 10 µg/ml E.coli DNA at 32°C overnight. The dried gels were subsequently washed in 2 x SSPE (SSPE is 10mM sodium phosphate pH7, 0.18M NaCl, 1mM EDTA) and 0.1% SDS at room temperature for 30 minutes and then at 40°C for 15 minutes in the same washing buffer. The result was similar to that observed on nitrocellulose filters (Figure 2). In order to remove background due to hybridisation to Daudi cell DNA, oligonucleotides 11 and 13 hybridise to DNA immobilised either in nitrocellulose or dried gels were cross-linked by ligation, as described in Example 1, and finally washed at 60°C for 15 minutes as above. This resulted in a single band corresponding to 1 ng of plasmid pIFS1101 with little observable background and with no signal evident corresponding to pK9 DNA as shown in Figure 3 for DNA immobilised on nitrocellulose.

### EXAMPLE 3

30 The plasmid DNA used for analysis was pIFS1101 (Edge et al., Nucleic Acids Research, vol. 11 (1983) p6419 to 6435). 2 µg of pIFS1101 plasmid DNA was digested with EcoRI (20 units, Bethesda Research Laboratories) in a reaction volume of 20 µl for 2 hours using conditions recommended by the enzyme supplier. The reaction mixture was extracted once with phenol: chloroform (1:1) and once with chloroform before adding 2 µl 3M sodium acetate pH 5.2 and 45 µl ethanol. The DNA was precipitated at -20°C overnight, washed in 70% EtOH and dried prior to resuspension in 30 µl H<sub>2</sub>O.

The oligonucleotides used for analysis were designated 11(-1) and 13 where oligonucleotide 13 was used to construct at the synthetic interferon alpha<sub>2</sub> gene in pIFS1101 and oligonucleotide 11(-1) is a derivative of oligonucleotide 11 used for gene construction with a sequence shifted 5' by 1 base. Thus the sequences of the oligonucleotides were as follows:-

Oligonucleotide 11(-1) 5' CCGTATCTCCCTGTT3'

Oligonucleotide 13 5' TCCTGTCTGAAAGAC3'

Oligonucleotide 13 was 5' end labelled with <sup>32</sup>P using polynucleotide kinase as described for synthetic linkers (forward reaction) in Molecular Cloning, a Laboratory Manual (Editors: Maniatis, Fritsch and Janbrock, Cold Spring Harbor). The kinase reaction was stopped by heating to 70°C for 10 minutes followed by 2 successive phenol extractions. The solution was then extracted with ether and excess ether was blown off.

4 µl aliquots of EcoRI digested pIFS1101 DNA were added to 50 µl aliquots of a solution of 10 x SSC, 1% NP40 and 0.5 µg/ml tRNA. 1 pmole aliquots of <sup>32</sup>P labelled oligonucleotide 13 either with or without 1 pmole of oligonucleotide 11(-1) was added and the solutions diluted to 100 µl with water. The solutions were heated to 100°C for 5 minutes and then placed in a water bath at 39°C for 2 hours in order for the oligonucleotides to hybridise to the target pIFS1101 DNA.

DNA samples were dissolved in 10 µl H<sub>2</sub>O to which was added 1 µl of either 2nM dCTP or 2nM dGTP (PL Biochemicals). Then 2.5 µl of 10 x nick translation buffer (see Molecular Cloning, a Laboratory Manual referred to above) 10 x buffer is 0.5 M Tris.HCl (pH 7.2), 0.1M MgSO<sub>4</sub>, 1mM dithiothreitol and 500 µg/ml BSA (Pentax, fraction V) was added and the solutions were diluted with water to 25µl. 2 Units of the Klenow fragment of DNA polymerase I (Boehringer) was added and the solutions incubated at room temperature for 30 minutes. 1.5 µl 10 x nick translation buffer was added together with 4 µl 10 mM ATP and 7.5 µl H<sub>2</sub>O. 2

units of T4 DNA ligase (Bethesda Research Laboratories) were added and the solutions were incubated at 14°C for 4 hours.

2 µl of reaction mixtures were analysed on an 8% native polyacrylamide gel. Prior to loading, samples were heated to 100°C for 5 minutes and rapidly cooled on ice before adding 1 µl of gel loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol and 15% Ficoll type 400). Figure 4 shows the results of this gel analysis. An autoradiographic signal corresponding to a 32 base long oligonucleotide marker band (lane M) was observed only in lane 1 where the polymerase reaction had included dCTP prior to ligase treatment. Other samples included polymerase treatment with dCTP present but without ligase treatment (lane 2) or without oligonucleotide 11(-1) (lane 5). Inclusion of dGTP in place of dCTP in the polymerase step either with ligase treatment (lane 3) or without ligase treatment (lane 4) did not result in an autoradiographic signal in the 32 base position.

These results indicate that production of the 32 base long ligation product derived from oligonucleotide 11(-1) and 13 requires inclusion of the correct deoxynucleotide triphosphate (dCTP) for filling in the single base pair gap opposite a G residue between the individually hybridised oligonucleotides. Inclusion of the incorrect nucleotide (e.g. dGTP) or, by inference, substitution of the G residue in the gap by an alternative residue, precludes the formation of the 32 base long ligation product. Thus this constitutes a diagnostic test for the presence or absence of a specific nucleotide in a target DNA sequence.

#### EXAMPLE 4

In a further exemplification of the invention a systematic study was performed on the effect of mismatches on ligation with T4 DNA ligase over a range of temperatures. Every possible mismatch possibility within one strand of a seven base-pair overlap was examined (Table 1). Ligation of mismatched oligonucleotides was assayed in competition experiments in the presence of equimolar quantities of the non-mismatched oligonucleotide CRN 1. The sequences correspond to the -35 region of the *E. coli trp* promoter Windass, J D et al Nucleic Acids Research 10, 6639-6657 (1982)). All oligonucleotides in this study were characterised by DNA sequencing (Maxam A M and Gilbert W., Proc. Natl. Acad. Sci. USA 74, 560-564 (1977)). Ligation products were quantified after separation by polyacrylamide gel electrophoresis by Cerenkov counting of radioactivity in putative product bands. In all cases where a mismatched oligonucleotide was ligated in the presence of the fully complementary oligonucleotide CRN 1 the yields of mismatched ligated product were minimal until the mismatched base was separated from the ligation point by 6 base pairs and until the temperature of the ligation reaction in these cases was less than 35°C.

**Table 1**

5		TGTTGACTGCCCCGT 3' CRN2
	<u>trp 3</u>	TGTTGACTGCC 3' CRN1
	5' ATTCTGAAATGAGC	
10		TTTACTCGACAAC TG 5'
	<u>trp 4</u>	
15	CRN 2	TG TT GA C TG CC CG T
	CRN6A	T
	CRN6B	A
20	CRN6C	G
	CRN5A	TG TT GT C TG CC CG T
	CRN5B	GC
25	CRN5C	GG
	CRN5D	TA
	CRN5E	CA
	CRN5F	AA
30	CRN4A	TG TC GA C TG CC CG T
	CRN4B	TA
	CRN4C	TG
35	CRN4D	CT
	CRN4E	AT
	CRN4F	GT
40	CRN3A	TT TT GA C TG CC CG T
	CRN3B	TC
	CRN3C	TA
45	CRN3D	CG
	CRN3E	AG
	CRN3F	GC

50 The region bearing the mismatch is the -35 region of the synthetic E. Coli trp promoter. In competition with CRN 1 for annealing to the 5' overlap from trp 4 are CRN2 (control) and CRN3A to 6C. These oligonucleotides cover all possible single base pair mismatches with the trp 4 5' overlap.

#### Materials and Methods

55

Oligonucleotides were synthesised by the improved solid phase phosphotriester method (Gait, M J et al (1980) Nucleic Acids Research 8, 1081-1096 and Markham, A F et al (1980) Nucleic Acid Research 8, 5193-5205) and purified by high performance liquid chromatography initially on Parisil 10-SAX anion-

exchange columns (Jones Chromatography, Glamorgan or Whatman Ltd) then on C<sub>18</sub>  $\mu$ Bondapak reverse phase columns (Waters Associates Inc.) as described (Newton, C R *et al* (1983) *Anal. Biochem.* **129**, 22-30).

Sequencing of 5' <sup>32</sup>P radiolabelled oligonucleotides were as described by Maxam and Gilbert (Maxam, A M *et al* (1977) *Proceeding of the National Academy of Sciences, USA* **74**, 560-564) for the cytosine plus thymine, adenine, and guanosine greater than adenine cleavages and as described by Rubin and Schmid (Rubin, C M *et al* (1980) *Nucleic Acids Research* **8**, 4613-4619) for the partial cytosine specific cleavage with hydroxylamine hydrochloride.

T4 DNA ligase was from Boehringer Mannheim GmbH and the unit definition used throughout is that according to Weiss *et al* (Weiss, B *et al* (1968) *Journal of Biological Chemistry* **243**, 4543-4555). One unit being the enzyme activity which exchanges at 37 °C 1 nmole <sup>32</sup>PPi into Norit absorbable material within 20 minutes. Ligase reactions were carried out in 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl<sub>2</sub>, 10 mM dithiothreitol and 0.4 mM ATP.

T4 polynucleotide kinase was from New England Biolabs, the unit definition being the enzyme activity producing 1 nmole of acid insoluble <sup>32</sup>P in 30 minutes at 37 °C. Kinase reactions were carried out in 50 mM Tris-HCl (pH 9.0), 10 mM MgCl<sub>2</sub>, 20 mM dithiothreitol, 0.1 mM spermidine, 0.1 mM EDTA. The ATP concentration was variable depending on the subsequent use of phosphorylated oligonucleotide.

Adenosine 5' -[ $\gamma$ -<sup>32</sup>P] triphosphate, triethylammonium salt (<sup>32</sup>P ATP) was from Amersham International, 1 mCi per ml in aqueous ethanol with specific activity > 5000 Ci/mmol.

Autoradiography was at room temperature or at -70 °C using Kodak XR-5 film with Ilford fast tungstate intensifying screens [Laskey, R A *et al* (1977) *Febs Letters* **82**, 314-341].

Electrophoresis was through 20% acrylamide (19.33% acrylamide, 0.67% bisacrylamide) gels containing 7M Urea, 50 mM Tris-borate (pH 8.3) 1 mM EDTA unless otherwise stated.

Electrophoresis samples were either resuspended or diluted with 80% formamide, 10 mM NaOH, 1 mM EDTA, 0.1% bromophenol blue. Samples were heat denatured at 100 °C for 2 minutes then rapidly cooled on ice prior to electrophoresis. Electrophoresis was across a potential gradient of 40V/cm till the bromophenol blue had migrated 15 cm from the origin unless stated otherwise.

<sup>32</sup>P labelled oligonucleotides were purified by polyacrylamide gel electrophoresis and DNA was recovered from gels by electroelution into dialysis bags containing 10 mM Tris-borate (pH 8.3), 0.2 mM EDTA (1 ml) across a potential gradient of 16V/cm for 45 minutes after which the polarity was reversed for 20 seconds. Electroeluates were concentrated by successive butanol extractions to a volume of approximately 500  $\mu$ l, extracted with phenol-chloroform [buffered with 0.5 M Tris-HCl (pH 7.5) then extracted with water] (500  $\mu$ l). Aqueous phases were extracted with ether (3 x 1 ml), further concentrated by butanol extraction to approximately 20  $\mu$ l, dried *in vacuo* and ethanol precipitated. Ethanol precipitation was accomplished by resuspending the DNA in 0.3 M sodium acetate (pH 5.6, 250  $\mu$ l) then addition and mixing of ethanol (800  $\mu$ l), chilling at -70 °C for 90 minutes or longer followed by centrifuging for 15 minutes in an Eppendorf microcentrifuge. The pellets were dried *in vacuo*, resuspended in water (500  $\mu$ l).

Cerenkov radiation was determined using an Intertechnique SL4000 Liquid Scintillation Counter with on line M1750 silent 700 printer. Electroeluates were transferred to siliconised 750 ml microcentrifuge tubes placed in 20  $\mu$ l standard plastic counting vials (Packard). Samples were allowed to dark adapt for 10 minutes then Cerenkov radiation determined by setting the Liquid Scintillation spectrometer to count for tritium. Bands from gels were excised, placed directly into plastic counting vials and Cerenkov radiation was determined as described for electroeluates. Quenching of Cerenkov radiation in gel bands relative to the same amount of <sup>32</sup>P-labelled oligonucleotide in solution could thus be allowed for.

#### **Mismatch competition reactions:**

A total of 220 competition reactions were performed. Each mismatch oligonucleotide or CRN2 (sequence control) were competed with CRN1 in a DNA Ligase assay at 0, 5, 10, 15, 20, 25, 30, 35 and 40 °C. In each case a 0 °C no enzyme control was included. All competitions were carried out in a volume of 60  $\mu$ l and contained trp 4 (5.0 pMole), trp 3 (7.5 pMole), CRN1 (7.5 pMole) and competing oligonucleotide (7.5 pMole). In molar concentrations total oligonucleotide was 456.5 nM, trp 4 was 83 nM, trp 3, CRN 1 and competitor were all 124.5 nM.

For each competing oligonucleotide a "competition mix" was prepared comprising competitor (75 pMole) and CRN1 (75 pMole) in aqueous solution (390  $\mu$ l). The competition mixes were divided into 10 equal portions. Both oligonucleotides were 5'-phosphorylated with <sup>32</sup>P -ATP and polynucleotide kinase. They were further purified by polyacrylamide gel electrophoresis, electroelution and ethanol precipitation as described above. Other reaction components were combined in a "trp mix" which contained trp 3

## EP 0 246 864 B1

(7.5pMole), trp 4 (5.0pMole) and 10X DNA ligase buffer (6  $\mu$ l) per 20  $\mu$ l.

For each temperature at which competition was studied, one aliquot of each competition mix and an aliquot of trp mix (200  $\mu$ l) was transferred to each competition mix and preincubated for 30 minutes. DNA ligase also, equilibrated at the requisite temperature was added (1 unit in  $\mu$ l) and mixed except to the 0 °C no enzyme controls where water (1  $\mu$ l) was added. Incubations were for 30 minutes and terminated by  
5 extraction with phenol/chloroform and stored at -70C prior to electrophoresis.

Aliquots (10  $\mu$ l) were removed from the aqueous phases of the reactions performed across the temperature range for each competition and these aliquots mixed with separate portions of formamide/NaOH/bromophenol blue (20  $\mu$ l) and electrophoresed as described. The series of temperature  
10 ranges for individual competitor oligonucleotides were run on separate gels which were autoradiographed as described (see Figures 5, 6 and 7).

Both bands from "0 °C no enzyme" control were excised and Cerenkov counted to determine the actual proportion of competing oligonucleotide relative to CRN1. The product band from CRN1 and the visible product bands from competitor were similarly isolated and Cerenkov counted. If no competitor product band  
15 was visible the area of gel was isolated where product was anticipated by inspection of the autoradiograph from the competition of CRN1 and CRN2. These bands were also Cerenkov counted to determine the proportion of mismatched product in the total product at each temperature.

Typical results after a 30 min ligation at 0 °C are presented in the Table. Where small amounts of mismatch ligation products were observed the yields of these were essentially constant at ligation  
20 temperatures of 0, 5, 10, 15, 20 and 25 °C.

Yields of mismatched products were consistently reduced by approximately 50% when ligation was performed at 30 °C and further reduced after incubation at 35 °C.

25

30

35

40

45

50

55

	Olig nucleotide	Mismatch	Mismatch product cpm	total product cpm	Σ Mismatch product
5	<hr/>				
10	CRN 2	NONE	547	1214	45.1
15	CRN 3A	T ACAACTG	8	1244	0.6
20	CRN 3B	C ACAACTG	6	1196	0.5
25	CRN 3C	A ACAACTG	36	1206	2.9
30	CRN 3D	C ACAACTG	19	1329	1.4
35	CRN 3E	A ACAACTG	8	1232	0.6
40	CRN 3F	G ACAACTG	10	1086	0.9
45	CRN 4A	C ACAACTG	12	963	1.2
	CRN 4B	A ACAACTG	12	1174	1.0

/continued....

	Oligonucleotide	Mismatch	Mismatch product cpm	total product cpm	% Mismatch product
5					
		G			
10	CRN 4C	ACAACTG	15	1183	1.3
		C			
15	CRN 4D	ACAACTG	13	1303	<del>1.0</del> <del>0.1</del>
		A			
20	CRN 4E	ACAACTG	24	1281	1.9
		G			
25	CRN 4F	ACAACTG	8	1208	0.7
		T			
30	CRN 5A	ACAACTG	67	1136	5.9
		C			
35	CRN 5B	ACAACTG	27	1328	2.0
		G			
40	CRN 5C	ACAACTG	22	1070	2.1
		T			
45	CRN 5D	ACAACTG	11	1201	0.9
		C			
	CRN 5E	ACAACTG	11	1281	0.9

/continued....



Olig nucleotide	Mismatch	Mismatch product cpm	total product cpm	% mismatch product
A				
CRN 5F	ACAACTG	23	1207	2.1
T				
CRN 6A	ACAACTG	498	1383	36.0
A				
CRN 6B	ACAACTG	421	1214	34.7
G				
CRN 6C	ACAACTG	418	1222	34.2

The results suggest that detection of point mutations in DNA should be possible by performing assays in the presence of appropriate pairs of oligonucleotides one of which is complementary to the normal sequence and one of which is complementary to the mutated sequence followed by analysis of the ligation products.

#### Claims

1. A method for discriminating between alternative nucleotide sequences, which method comprises subjecting adjacent segments of a target base sequence to hybridisation with a detectable first nucleotide probe and with a second nucleotide probe, to form a hybrid, the nucleotide sequence of the first and second probe being such that where they form a split probe hybrid with a complementary target sequence they may subsequently be linked, subjecting any hybrid obtained to linkage, and detection of any hybrid obtained;  
the DNA sequence of the detectable first nucleotide probe and of the second nucleotide probe being such that a potential mismatch in the target sequence lies either between the said probes or at the terminal end of one of said probes which is contiguous with the other of the said probes;  
the method being effected such that a complementary target sequence is discriminated from a target sequence with one or more non-complementary nucleotides.
2. A method as claimed in claim 1 wherein the detectable first nucleotide probe and second nucleotide probe are hybridised to each side of a potential variant sequence in a target sequence the said probes being subjected to a linkage reaction which comprises introducing a nucleotide(s) complementary to either the normal or the suspected variant sequence and subjecting the nucleotide(s) to ligation; followed by detection of any hybrid obtained
3. A method as claimed in claim 2 wherein detection is effected by subjecting any hybrid obtained to selective denaturing whereby any hybrid present, in which linkage of the detectable first nucleotide probe to the second nucleotide probe has not been effected, is denatured.
4. A method as claimed in claim 2 or claim 3 wherein the introduction of the said nucleotide(s) is effected by the use of DNA polymerase.

5. A method as claimed in any one of claims 2 to 4 wherein the detectable first nucleotide probe and second nucleotide probe are such that they hybridise to the target sequence whereby to leave a gap of a single nucleotide between the said probes.
- 5 6. A method as claimed in claim 1 in which a split probe would be formed following hybridisation, with a complementary target base sequence, any hybrid obtained being subjected to a linking reaction for linking the detectable first nucleotide probe to the second nucleotide probe, and the hybrid thus obtained being subjected to appropriate treatment whereby any hybrid present, in which linkage of the detectable first nucleotide probe to second nucleotide probe has not been effected, is denatured  
10 whereas no denaturation is effected for a perfectly complementary detectable linked oligonucleotide-target sequence hybrid.
7. A method as claimed in claim 1 wherein, adjacent segments of the target base sequence are subjected to hybridisation with a detectable first nucleotide probe and with a second nucleotide probe such that  
15 a split probe hybrid would be formed with a complementary target sequence, the hybrid obtained being subjected to selective denaturing whereby to denature whichever of the first and second nucleotide probes is hybridised to a portion of the target base sequence with one or more non-complementary nucleotides the hybrid obtained subsequently being subjected to a linking reaction whereby to link together the detectable first nucleotide probe to the second nucleotide probe, and subjecting the hybrid  
20 obtained to selective denaturation, whereby to discriminate between a target sequence complementary to the first and second nucleotide probes and a target sequence with one or more nucleotides non-complementary to one of the first and second nucleotide probes.
8. A method as claimed in claim 1 for the analysis of translocations in a target base sequence wherein the  
25 detectable first nucleotide probe is adapted to hybridise across a region of potential translocation(s) and the non-detectable second nucleotide probe is adapted to hybridise to sequences adjacent to said potential translocation(s), the non-detectable second nucleotide probe carrying one member of a binding pair, the method comprising formation of a split probe hybrid which is subjected to linking to form a linked probe hybrid which hybrid is then denatured.  
30
9. A method as claimed in claim 1 wherein each of the detectable first nucleotide probe and second nucleotide probe carry a moiety such that after hybrid formation, and denaturation where appropriate, a signal is only detectable if a nucleotide sequence is obtained which carries both the moiety attached to the detectable first nucleotide probe and the moiety attached to the second nucleotide probe.  
35
10. A method as claimed in claim 1 for discriminating between alternative nucleotide sequences in which a target sequence is subjected to hybridisation with more than two oligonucleotide probes such that where a complementary target sequence is present a split probe hybrid is obtained, the detectable first nucleotide probe being a terminal oligonucleotide probe which is detectable and the second nucleotide  
40 probe being the other terminal oligonucleotide probe which has attached thereto one member of a binding pair, individual other oligonucleotide probes(s) being hybridised separately but adjacently to a contiguous target sequence between the said terminal oligonucleotide probes, the hybrid obtained is then subjected to selective denaturation whereby to denature any oligonucleotide probe hybridised to the target sequence across a base pair mismatch, and the individual oligonucleotide probes linked to  
45 join the detectable oligonucleotide probe to the oligonucleotide probe having one member of a binding pair attached thereto to form a linked probe hybrid which is then denatured and contacted with the other member of the binding pair whereby the detectable linked probe nucleotide sequence including the said binding pair may be separated from other nucleotide sequences.
- 50 11. A split probe hybrid comprising a detectable first nucleotide probe and a second nucleotide probe hybridised to adjacent segments of a target base sequence, the detectable first nucleotide probe being capable of linkage to the second nucleotide probe, characterised in that the detectable first nucleotide probe and/or the second nucleotide probe are hybridized to either side of a variant sequence associated with a disease state or to the corresponding normal sequence; or are hybridised to the  
55 target base sequence such that a variant base sequence associated with a disease state therein is at the terminal end of one of said probes, which terminal end is contiguous with the other of said probes or are hybridised to the corresponding normal sequence.

12. A kit for discriminating between alternative nucleotide sequences according to the method of claim 1, which comprises a detectable first nucleotide probe and a second nucleotide probe, each probe having a nucleotide sequence homologous to adjacent segments of a target sequence, a potential variant sequence being present in one of said segments or therebetween; the detectable first nucleotide probe and/or the second nucleotide probe being such that a potential variant sequence is at the terminal end of one of said probes, which terminal end is contiguous with the other of said probes or the potential variant sequence is present between said probes, the kit additionally containing a reagent(s) for linking said probes.
13. A kit as claimed in claim 12 which contains a detectable first nucleotide probe and second nucleotide probe for detecting a point mutation associated with a disease state as well as a detectable first nucleotide probe and a second nucleotide probe for detecting the corresponding normal sequence in which the point mutation was absent.

#### 15 Patentansprüche

1. Verfahren zur Diskriminierung zwischen alternativen Nucleotidsequenzen, wobei das Verfahren umfaßt: das Unterziehen benachbarter Segmente einer Targetbasensequenz der Hybridisierung mit einer nachweisbaren ersten Nucleotidsonde und mit einer zweiten Nucleotidsonde zur Bildung eines Hybrids, wobei die Nucleotidsequenz der ersten und der zweiten Sonde derart sind, daß, falls sie ein Splitsondenhybrid mit einer komplementären Targetsequenz bilden, sie anschließend aneinander gebunden werden können, das Unterziehen irgendeines erhaltenen Hybrids der Bindung und den Nachweis irgendeines erhaltenen Hybrids, wobei die DNA-Sequenz der nachweisbaren ersten Nucleotidsonde und der zweiten Nucleotidsonde derart sind, daß ein potentieller Fehler in der Targetsequenz entweder zwischen diesen Sonden oder an dem endständigen Ende von einer dieser Sonden, welche an die andere dieser Sonden angrenzt, liegt; das Verfahren so durchgeführt wird, daß eine komplementäre Targetsequenz von einer Targetsequenz mit einem oder mehreren nicht-komplementären Nucleotiden diskriminiert wird.
2. Verfahren nach Anspruch 1, worin die nachweisbare erste Nucleotidsonde und zweite Nucleotidsonde an jeder Seite einer potentiellen Varianzsequenz in einer Targetsequenz hybridisiert werden, wobei diese Sonden einer Bindungsreaktion unterworfen werden, welche die Einführung eines Nucleotids/von Nucleotiden, das/die entweder zu der normalen oder der zu erwartenden Varianzsequenz komplementär ist/sind, und das Unterziehen des Nucleotids/der Nucleotide der Bindungsbildung umfaßt; gefolgt vom Nachweis irgendeines erhaltenen Hybrids.
3. Verfahren nach Anspruch 2, worin der Nachweis durch Unterziehen irgendeines erhaltenen Hybrids der selektiven Denaturierung durchgeführt wird, wodurch irgendein vorhandenes Hybrid, in welchem die Bindung der nachweisbaren ersten Nucleotidsonde an die zweite Nucleotidsonde nicht durchgeführt wurde, denaturiert wird.
4. Verfahren nach Anspruch 2 oder Anspruch 3, worin die Einführung des/der Nucleotids/e durch Verwendung von DNA-Polymerase durchgeführt wird.
5. Verfahren nach einem der Ansprüche 2 bis 4, worin die nachweisbare erste Nucleotidsonde und die zweite Nucleotidsonde derart sind, daß sie an die Targetsequenz hybridisieren, wodurch ein Lücke eines einzelnen Nucleotids zwischen diesen Sonden belassen wird.
6. Verfahren nach Anspruch 1, worin eine Splitsonde im Anschluß an die Hybridisierung mit einer komplementären Targetbasensequenz gebildet würde, wobei irgendein erhaltenes Hybrid einer Bindungsreaktion zum Binden der nachweisbaren ersten Nucleotidsonde an die zweite Nucleotidsonde unterzogen wird, und das so erhaltene Hybrid einer geeigneten Behandlung unterzogen wird, wodurch irgendwelches vorhandenes Hybrid, in dem Bindung der nachweisbaren ersten Nucleotidsonde an zweite Nucleotidsonde nicht erfolgte, denaturiert wird, während keine Denaturierung für eine perfekt komplementäres, nachweisbares, gebundenes Oligonucleotid-Targetsequenzhybrid erfolgt.
7. Verfahren nach Anspruch 1, worin benachbarte Segmente der Targetbasensequenz der Hybridisierung mit einer nachweisbaren ersten Nucleotidsonde und mit einer zweiten Nucleotidsonde derart unterzo-

gen werden, daß ein Splitsondenhybrid mit einer komplementären Targetsequenz gebildet wird, das erhaltene Hybrid selektiver Denaturierung unterzogen wird, wodurch eine beliebige der ersten und zweiten Nucleotidsonden, die an einen Abschnitt der Targetbasensequenz mit einem oder mehreren nicht-komplementären Nucleotid/en hybridisiert ist, denaturiert wird, das erhaltene Hybrid anschließend einer Bindungsreaktion unterworfen wird, wodurch die nachweisbare erste Nucleotidsonde mit der zweiten Nucleotidsonde verbunden wird, und das erhaltene Hybrid selektiver Denaturierung unterworfen wird, wodurch zwischen einer zu der ersten und zweiten Nucleotidsonde komplementären Targetsequenz und einer Targetsequenz mit einem oder mehreren Nucleotiden nichtkomplementär zu einer der ersten und zweiten Nucleotidsonde diskriminiert wird.

10

8. Verfahren nach Anspruch 1 für die Analyse von Verschiebungen in einer Targetbasensequenz, worin die nachweisbare erste Nucleotidsonde geeignet ist, über einen Bereich von potentieller/n Verschiebung/en zu hybridisieren und die nicht-nachweisbare zweite Nucleotidsonde geeignet ist, an Sequenzen benachbart zu dieser/n potentiellen Verschiebungen zu hybridisieren, wobei die nicht-nachweisbare zweite Nucleotidsonde ein Glied eines Bindungspaares trägt, wobei das Verfahren die Bildung eines Splitsondenhybrids umfaßt, welches der Bindung zur Bildung eines gebundenen Sondenhybrids unterworfen wird, welches Hybrid dann denaturiert wird.

15

9. Verfahren nach Anspruch 1, worin jede der nachweisbaren ersten Nucleotidsonde und zweiten Nucleotidsonde eine solche Einheit tragen, daß nach der Hybridbildung und Denaturierung, falls angebracht, ein Signal nur nachweisbar ist, wenn eine Nucleotidsequenz erhalten wird, die sowohl die an die nachweisbare erste Nucleotidsonde gebundene Einheit als auch die an die zweite Nucleotidsonde gebundene Einheit trägt.

20

10. Verfahren nach Anspruch 1, zur Diskriminierung zwischen alternativen Nucleotidsequenzen, in welchem eine Targetsequenz der Hybridisierung mit mehr als zwei Oligonucleotidsonden derart unterworfen wird, daß, wo eine komplementäre Targetsequenz vorhanden ist, ein Splitsondenhybrid erhalten wird, wobei die nachweisbare erste Nucleotidsonde eine endständige Oligonucleotidsonde ist, welche nachweisbar ist, und die zweite Nucleotidsonde die andere endständige Oligonucleotidsonde ist, welche hieran gebunden ein Glied eines Bindungspaares hat, wobei individuelle andere Oligonucleotidsonde/n getrennt jedoch benachbart zu einer angrenzenden Targetsequenz zwischen diesen endständigen Oligonucleotidsonden hybridisiert werden, das erhaltene Hybrid dann selektiver Denaturierung unterworfen wird, wodurch irgendwelche an die Targetsequenz über einen Basenpaarfehler hybridisierte Oligonucleotidsonde denaturiert wird, und die individuellen Oligonucleotidsonden gebundenen werden, um die nachweisbare Oligonucleotidsonde an die Oligonucleotidsonde, welche ein Glied eines Bindungspaares hieran gebunden aufweist, zur Bildung eines gebundenen Sondenhybrids zu vereinigen, welches dann denaturiert und mit dem anderen Glied des Bindungspaares kontaktiert wird, wodurch die nachweisbare gebundene Sonden-nucleotidsequenz einschließlich dieses Bindungspaares von anderen Nucleotidsequenzen abgetrennt werden kann.

40

11. Splitsondenhybrid, umfassend eine nachweisbare erste Nucleotidsonde und eine zweite Nucleotidsonde, hybridisiert an angrenzende Segmente einer Targetbasensequenz, wobei die nachweisbare erste Nucleotidsonde zur Bindung mit der zweiten Nucleotidsonde fähig ist, dadurch gekennzeichnet, daß die nachweisbare erste Nucleotidsonde und/oder die zweite Nucleotidsonde an beide Seite einer mit einem Krankheitszustand assoziierten Varianzsequenz oder an die entsprechende Normalsequenz hybridisiert sind; oder an die Targetbasensequenz derart hybridisiert sind, daß eine mit einem Krankheitszustand assoziierte Varianzbasensequenz hierin am endständigen Ende einer dieser Sonden ist, wobei dieses endständige Ende mit dem anderen dieser Sonden anstoßend ist, oder mit der entsprechenden Normalsequenz hybridisiert sind.

50

12. Kit zur Diskriminierung zwischen alternativen Nucleotidsequenzen nach dem Verfahren nach Anspruch 1, welches umfaßt eine nachweisbare erste Nucleotidsonde und eine zweite Nucleotidsonde, wobei jede Sonde eine zu angrenzenden Segmenten einer Targetsequenz homologe Nucleotidsequenz hat, eine potentielle Varianzsequenz in einem dieser Segmente oder dazwischen vorhanden ist; die nachweisbare erste Nucleotidsonde und/oder die zweite Nucleotidsonde derart sind, daß eine potentielle Varianzsequenz an dem endständigen Ende einer dieser Sonden ist, wobei dieses endständige Ende anstoßend an die andere dieser Sonden ist, oder die potentielle Varianzsequenz zwischen diesen Sonden vorhanden ist, wobei das Kit zusätzlich ein Reagens(tien) zum Verbinden dieser Sonden enthält.

55

13. Kit nach Anspruch 12, welches eine nachweisbare erste Nucleotidsonde und eine zweite Nucleotidsonde zum Nachweis einer mit einem Krankheitszustand assoziierten Punktmutation wie auch eine nachweisbare erste Nucleotidsonde und eine zweite Nucleotidsonde zum Nachweis der entsprechenden Normalsequenz, in welcher die Mutationssequenz fehlt, enthält.


5

## Revendications

1. Procédé pour distinguer entre deux séquences de nucléotides, consistant à soumettre des segments adjacents d'une séquence de base cible à une hybridation avec une première sonde de nucléotides détectable et une seconde sonde de nucléotides, pour former un hybride, la séquence de nucléotides de la première et de la seconde sondes étant telle qu'à l'endroit où elles forment un hybride de sondes scindé avec une séquence cible complémentaire, elles peuvent ensuite être liées, à soumettre tout hybride obtenu à une liaison et à détecter tout hybride éventuellement obtenu ;  
la séquence d'ADN de la première sonde de nucléotides détectable et de la seconde sonde de nucléotides étant telle qu'une erreur d'appariement potentielle dans la séquence cible réside soit entre ces sondes, soit à l'extrémité terminale d'une de ces sondes qui est contiguë à l'autre sonde ;  
le procédé étant effectué en distinguant une séquence cible complémentaire d'une séquence cible avec un ou plusieurs nucléotides non complémentaires.
2. Procédé selon la revendication 1, dans lequel la première sonde de nucléotides détectable et la seconde sonde de nucléotides sont hybridées à chaque côté d'une séquence variante potentielle d'une séquence cible, ces sondes étant soumises à une réaction de liaison qui consiste à introduire un ou plusieurs nucléotides complémentaires soit à la séquence normale, soit à la séquence variante soupçonnée et à soumettre le ou les nucléotides à une ligature ; puis à détecter tout hybride obtenu.
3. Procédé selon la revendication 2, dans lequel la détection est effectuée en soumettant tout hybride obtenu à une dénaturation sélective de sorte que tout hybride présent, dans lequel la liaison de la première sonde de nucléotides détectable à la seconde sonde de nucléotides n'a pas été effectuée, est dénaturé.
4. Procédé selon la revendication 2 ou 3, dans lequel l'introduction de ce ou ces nucléotides est effectuée en utilisant de l'ADN polymérase.
5. Procédé selon l'une quelconque des revendications 2 à 4, dans lequel la première sonde de nucléotides détectable et la seconde sonde de nucléotides sont telles qu'elles s'hybrident à la séquence cible de manière à laisser une brèche d'un seul nucléotide entre ces sondes.
6. Procédé selon la revendication 1, dans lequel une sonde scindée serait formée après l'hybridation avec une séquence de bases cible complémentaire, tout hybride obtenu étant soumis à une réaction de liaison pour lier la première sonde de nucléotides détectable à la seconde sonde de nucléotides, l'hybride ainsi obtenu étant soumis à un traitement approprié dans lequel tout hybride présent, dans lequel la liaison de la première sonde de nucléotides détectable à la seconde sonde de nucléotides n'a pas été effectuée, est dénaturé, tandis qu'aucune dénaturation n'est effectuée pour un hybride oligonucléotide lié détectable - séquence cible parfaitement complémentaire.
7. Procédé selon la revendication 1, dans lequel des segments adjacents de la séquence de bases cible sont soumis à une hybridation avec une première sonde de nucléotides détectable et avec une seconde sonde de nucléotides de telle sorte qu'un hybride de sonde scindée soit formé avec une séquence cible complémentaire, l'hybride obtenu étant soumis à une dénaturation sélective pour dénaturer ainsi celle des première et seconde sondes qui est hybridée à une partie de la séquence de bases cible avec un ou plusieurs nucléotides non complémentaires, l'hybride obtenu étant soumis ultérieurement à une réaction de liaison de manière à lier l'une à l'autre la première sonde de nucléotides détectable à la seconde sonde de nucléotides et en soumettant l'hybride obtenu à une dénaturation sélective pour distinguer ainsi entre une séquence cible complémentaire de la première et de la seconde sondes de nucléotides et une séquence cible contenant un ou plusieurs nucléotides non complémentaires à l'une des première et seconde sondes de nucléotides.

8. Procédé selon la revendication 1 pour l'analyse de translocations dans une séquence de bases cible dans lequel la première sonde de nucléotides détectable est conçue pour s'hybrider à travers une région de translocation(s) potentielle(s) et la seconde sonde de nucléotides non détectable est conçue pour s'hybrider à des séquences adjacentes à cette ou à ces translocation(s) potentielle(s), la seconde sonde de nucléotides non détectable portant un membre d'une paire de liaisons, le procédé comprenant la formation d'un hybride de sonde scindée qui est soumis à une liaison pour former un hybride de sonde liée, lequel hybride est ensuite dénaturé.
9. Procédé selon la revendication 1, dans lequel la première sonde de nucléotides détectable et la seconde sonde de nucléotides portent chacune une partie telle qu'après formation de l'hybride et dénaturation si celle-ci est appropriée, un signal n'est détectable que si l'on obtient une séquence de nucléotides qui porte à la fois la partie fixée à la première sonde de nucléotides détectable et la partie fixée à la seconde sonde de nucléotides.
10. Procédé selon la revendication 1 pour distinguer entre deux séquences de nucléotides, dans lequel une séquence cible est soumise à une hybridation avec plus de deux sondes d'oligonucléotides de telle sorte que lorsqu'une séquence cible complémentaire est présente, on obtient un hybride de sonde scindée, la première sonde de nucléotides détectable étant une sonde de nucléotides terminale qui est détectable et la seconde sonde de nucléotides étant l'autre sonde d'oligonucléotides terminale à laquelle est fixé un membre d'une paire de liaisons, une ou plusieurs autres sonde(s) d'oligonucléotides individuelles étant hybridées séparément, mais en position adjacente à une séquence cible contiguë entre ces sondes d'oligonucléotides terminales, l'hybride obtenu est ensuite soumis à une dénaturation sélective de manière à dénaturer toute sonde d'oligonucléotides hybridée à la séquence cible à travers une erreur d'appariement des paires de base et les sondes d'oligonucléotides individuelles étant liées pour unir la sonde d'oligonucléotides détectable à la sonde d'oligonucléotides sur laquelle est fixé un membre d'une paire de liaisons pour former un hybride de sonde liée qui est ensuite dénaturée et mise en contact avec l'autre membre de la paire de liaisons, grâce à quoi la séquence de nucléotides de la sonde liée détectable contenant cette paire de liaisons peut être séparée des autres séquences de nucléotides.
11. Hybride de sonde scindée comprenant une première sonde de nucléotides détectable et une seconde sonde de nucléotides hybridée à des segments adjacents d'une séquence de base cible, la première sonde de nucléotides détectable étant capable de se lier à la seconde sonde de nucléotides, caractérisé en ce que la première sonde de nucléotides détectable et/ou la seconde sonde de nucléotides sont hybridées à l'un et l'autre côté d'une séquence variante associée à un état pathologique ou à la séquence normale correspondante ; ou sont hybridées à la séquence de base cible de telle sorte qu'une séquence de base variante associée à un état pathologique dans celle-ci est à l'extrémité terminale de l'une de ces sondes, laquelle extrémité terminale est contiguë à l'autre sonde, ou sont hybridées à la séquence normale correspondante.
12. Nécessaire pour distinguer entre deux séquences de nucléotides selon le procédé de la revendication 1, qui comprend une première sonde de nucléotides détectable et une seconde sonde de nucléotides, chacune des sondes ayant une séquence de nucléotides homologue aux segments adjacents d'une séquence cible, une séquence variante potentielle étant présente dans un des segments ou entre eux ; la première sonde de nucléotides détectable et/ou la seconde sonde de nucléotides étant telle qu'une séquence variante potentielle soit à l'extrémité terminale d'une de ces sondes, laquelle extrémité terminale est contiguë à l'autre sonde et la séquence variante potentielle est présente entre ces sondes, le nécessaire contenant en outre un ou plusieurs réactifs pour lier ces sondes.
13. Nécessaire selon la revendication 12, qui contient une première sonde de nucléotides détectable et une seconde sonde de nucléotides pour détecter une mutation ponctuelle associée à un état pathologique ainsi qu'une première sonde de nucléotides et une seconde sonde de nucléotides pour détecter la séquence normale correspondante dans laquelle la mutation ponctuelle est absente.

*Fig. 1.*




*Fig. 2.*



*Fig. 3.*




*Fig.4.*






*Fig.5.*



*Fig.6.*



*Fig. 7.*

